Title,Summary,Date
3 EV Stocks to Buy on the Dip: March 2024,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-03-29
3 EV Stocks to Buy for the Next Bull Run: March 2024,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-03-28
Tiziana Life Sciences Announces Podium Presentation at AD/PD of Nasal Anti-CD3 in Alzheimer’s Disease,"Data shows reduction of microglia activation and improvement in behavior in rodent models of Alzheimer’s disease (AD) and Parkinson’s disease (PD)Nasal anti-CD3 reduced hemorrhage and edema that occurs with ARIA based on animal studiesNeuroinflammation modulation may be synergistic to approved treatments in Alzheimer’s Disease NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-",2024-03-05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-03-05
Tiziana Life Sciences to present at AD/PD of nasal anti-CD3 in Alzheimer's,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-03-05
Tiziana Life Sciences Ltd at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-02-09
7 Over-Hyped Stocks to Sell Before They Plunge,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-01-25
TLSA: First Phase II SPMS Patient Dosed,"By John Vandermosten, CFA NASDAQ:TLSA Tiziana Life Sciences PLC (NASDAQ:TLSA) has achieved a significant milestone dosing its first patient in its Phase IIa study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). The company also recently dosed four new patients in its expanded access (EA) multiple sclerosis",2024-01-09
Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients,"NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in mi",2024-01-08
"Tiziana Life Sciences announces updated clinical, PET scan findings",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-01-08
"Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024","NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD",2024-01-05
Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity - Associated Inflammation,"NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation associated with Type 2 Diabetes (T2D) and also in a separate population of patients",2024-01-05
"Tiziana Life files new patent application related to GLP-1ra, foralumab",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2024-01-05
"Tiziana Life Sciences Ltd Reports Earnings Results for the Half Year Ended June 30, 2023","Tiziana Life Sciences Ltd reported earnings results for the half year ended June 30, 2023. For the half year, the company reported net loss was USD 8.62 million compared to USD 4.51 million a year...",2023-12-30
Tiziana Life Sciences : Updated Interim Results for the Six Months Ended 30 June 2023 - Form 6-K,"Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 - Tiziana Life Sciences, Ltd. , a biotechnology company developing breakthrough...",2023-12-29
Tiziana Life Sciences : Interim Results for the Six Months Ended 30 June 2023 863.7 KB,"Tiziana Life Sciences Ltd Updated Interim Results for the Six Months Ended 30 June 2023 NEW YORK, December 29, 2023 -...",2023-12-29
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis,"NEW YORK, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis (na-SPMS). Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up t",2023-12-19
Tiziana Life doses first patient in Phase 2a trial of intranasal foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-12-19
"Tesla Shares Hardly Damaged Despite Recall: Full Self-Driving Is Elon Musk's 'Holy Grail,' Analyst Says",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-12-13
Don't Get Caught In Equity Rally Hype: Lessons From 2023 To Remember In 2024,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-12-12
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar,"NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE! with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana’s recent c",2023-12-04
Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect : Biotech Investment Webinar,"NEW YORK, Dec. 04, 2023 -- Tiziana Life Sciences Ltd.  , a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew...",2023-12-04
Tiziana Life Sciences : Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK - Form 6-K,Tiziana Life Sciences Ltd Notice of Annual General Meeting of Shareholders on Thursday 14th December 2023 at 8.30am EST/ 1.30pm UK TO BE HELD AS A REMOTE MEETING...,2023-12-01
Tiziana Life Sciences Announces Foralumab Dosing of Four New Patients in the Expanded Access Program for Multiple Sclerosis,"NEW YORK, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the company has successfully enrolled and dosed four new patients with non-active secondary progressive multiple sclerosis (na-SPMS) in the Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System Expanded Access (EA) Pr",2023-11-30
Tiziana Expects To Start Enrolling Patients In Its Phase 2 Clinical Trial To Treat Secondary Progressive Multiple Sclerosis (SPMS) Using Its Novel Intranasal Monoclonal Antibody Foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-11-30
Tiziana Life Sciences announces foralumab dosing of four patients in EA program,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-11-30
"SPDR ETF Report For Tuesday, November 21",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-11-22
"Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023","NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully hu",2023-11-01
TLSA: Six Month SPMS Results,"By John Vandermosten, CFA NASDAQ:TLSA In a series of press releases released over the first half of October, Tiziana Life Sciences PLC (NASDAQ:TLSA) announced impressive results for its expanded access (EA) cohort of six patients who were receiving intranasal foralumab to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The six-month results span multiple parameters and",2023-10-20
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-19
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment,"Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to anti-CD3 Foralumab Has Been Well-ToleratedAt-Home Dosing Likely to Improve Patient Compliance to Treatment and Outcomes NEW YORK, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation ther",2023-10-18
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-18
Tiziana Life announces allowance by FDA for at-home dosing of Foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-18
12 Health Care Stocks Moving In Wednesday's After-Market Session,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-18
12 Health Care Stocks Moving In Tuesday's Intraday Session,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-17
"Tiziana Life Sciences reveals ""exciting"" clinical data from latest MS trial",Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company ann...,2023-10-17
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab,"Numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL™ Fatigue scores.Data was presented at ECTRIMS (39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis) on October 11, 2023 NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology compan",2023-10-16
Tiziana Life Sciences announces six-month clinical results of foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-16
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS),"Figure 1 Six-Month PET Scan Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyPhase 2 trial screening for na-SPMS to begin in November 2023 NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a bio",2023-10-13
Tiziana announces positive six-month PET scan results for intranasal Alzheimer’s drug,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-13
Tiziana Life Sciences announces six-month PET scan results with foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-13
"Tiziana To Announce Six-Month Human Safety And Biomarker Data At The ECTRIMS Annual Congress, Following-Up From Positive Outcomes Data Presented In June",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-12
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress,"Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes” NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a late breaking poster titled, “Treatment Of Six Non-Active Se",2023-10-11
Tiziana Life Sciences announces late breaking poster on Foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-11
Tiziana Advances Phase 2 Site Selection For Its Lead Clinical Program In Non-Active Secondary Progressive Multiple Sclerosis (SPMS) And The Company Prepares For Six-Month Clinical Data Update,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-04
Latest AI Quantum Computing News And Company Stock Performances YTD,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-10-03
Tiziana Life Sciences Prepares To Advance Lead Intranasal Foralumab Program In First-Of-Its-Kind Phase 2a Clinical Trial for Non-Active SPMS Patients,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-27
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis,"NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal investigators at Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testin",2023-09-26
Tiziana Life Sciences initiates Phase 2a trial of intranasal foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-26
Thailand's new prime minister courts US companies for investment,"Thailand's new Prime Minister Srettha Thavisin met with U.S. companies including Microsoft, Google, and Estee Lauder in his first trip abroad since coming to power last month, looking to draw investment to boost a flagging economy.",2023-09-22
Tesla Cybertruck To Be Used For Oracle's Next-Gen Police Car,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-20
MEDIA : BioWorld,"Sep. 12, 2023 By Mar de Miguel Alzheimer's disease has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody reduced microglia activation in...",2023-09-12
Tiziana Life Sciences' Alzheimer's treatment validated in new study,Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after the clinical-stage biopharmaceutical company ann...,2023-09-12
Tiziana Reveals Alzheimer's Research Milestone With PNAS Journal After FDA IND Green Light,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-12
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,"NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023. Event:H.C. Wainwright 25th Annual Global Investment ConferenceDate:Presentation to be acc",2023-09-08
B.Riley Financial Sticks to Its Buy Rating for Tiziana Life Sciences (TLSA),Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-08
"Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance","The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for human study in mild to moderate Alzheimer’s DiseaseThe publication shows anti-CD3 monoclonal antibody (mAb) administered intranasally, ameliorates disease in a 3xTg model of Alzheimer’s disease by targeting microglial activation in the brain, wh",2023-09-06
Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-06
"Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance",The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease ”FDA has cleared the IND for intranasal...,2023-09-06
Tiziana Life Sciences announces publication on intranasal foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-09-06
"BMW expects higher China sales in 2023, finance chief says","BMW expects to sell more cars in China this year despite a local price war in the electric vehicle (EV) segment, and muted demand overall, the luxury carmaker's chief financial officer (CFO) said at the IAA car show in Munich.",2023-09-02
Tiziana Life Sciences : At Market Issuance Sales Agreement - Form 6-K,"INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K On September 1, 2023, Tiziana Life Sciences Ltd. entered into an At Market Issuance Sales Agreement with B. Riley Securities,...",2023-09-01
TLSA: IND Cleared by FDA and Alzheimer’s Deep Dive,"By John Vandermosten, CFA NASDAQ:TLSA Tiziana Life Sciences PLC (NASDAQ:TLSA) announced the clearance of its Investigational New Drug (IND) application for its anti-CD3 foralumab in Alzheimer’s Disease (AD) in an August 15th press release . Foralumab is now the subject of a Phase II clinical trial in AD building on other work being done in an ongoing non-active secondary progressive multiple",2023-08-28
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer,"Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023.",2023-08-23
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology,"NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal anti-CD3 mAb induces Tregs that dampen microglial activation and treat neuroinflammatory diseases including MS, AD and ALS” at the 16th International Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada, being held",2023-08-23
Tiziana Life Sciences appoints William Clementi as chief development officer,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-23
Tiziana Life Sciences announces Foralumab presentation at ISNI meeting,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-23
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease,"NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard L. Weiner, a thought leader in the field of neurology and immunology, was featured in an exclusive live interview on Bloomberg to discuss the Company’s latest announcement on its advancement of the novel foralumab program in Alzheimer's disea",2023-08-17
Tiziana's Intranasal Foralumab For Alzheimer's Treatment Gets FDA Nod For Phase 2 Trials Under Brigham And Women's Hospital Supervision,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-16
Media : Neurology Live Coverage,"FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease Aug 15, 2023 Isabella Ciccone, MPH Foralumab, a therapy designed to bind to T...",2023-08-16
Tiziana Life Sciences gets FDA green light to investigate potential Alzheimer's treatment,Tiziana Life Sciences Ltd (NASDAQ:TLSA) chief medical officer and chief operating officer Matthew Davis speaks to Thomas Warner from Proactive after announcing that Tiziana has received FDA clearan...,2023-08-15
"Nvidia climbs, D.R. Horton gets a Buffett boost, and other stocks on the move",Nvidia was the subject of two bullish analyst notes on Tuesday.,2023-08-15
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease,"Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women’s Hospital, a founding member of Mass General Brigham Healthcare System NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S.",2023-08-15
Tiziana Life Sciences (NASDAQ:TLSA) Jumps 45% as FDA Greenlights Alzheimer Trial,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-15
Tiziana Life Sciences’ stock soars 54% premarket after FDA clear path for trial of intranasal treatment for Alzheimer’s disease,"Tiziana Life Sciences Ltd.’s stock soared 54% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug...",2023-08-15
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease,"Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women’s Hospital, a founding...",2023-08-15
Tiziana climbs as FDA clears trial for intranasal Alzheimer’s drug,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-15
Tiziana Life Sciences’ stock soars 41% premarket after FDA clear path for trial of intranasal treatment for Alzheimer’s disease,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-15
Tiziana Life Sciences announces FDA IND clearance of intranasal foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-15
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-15
Ford's China joint venture to partner with Chongqing Changan Automobile on new-energy car,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-11
"As Tiziana Life Sciences (NASDAQ: TLSA) Prepares For Phase 2 Trials, Have They Successfully Derisked Foralumab?",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-08
"Tiziana (NASDAQ: TLSA) Continues The Fight Against Multiple Sclerosis, Will Announce 6-Month Results For Its Novel Treatment Soon",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-03
"Proactive Analyst expects ""some good news over the next 1-2 months"" from Tiziana Life Sciences","Proactive Research Analyst Robin Davidson talks to Thomas Warner about his new research note on Tiziana Life Sciences Ltd, which focuses on what he expects from the clinical-stage biopharmaceutical...",2023-08-01
12 Health Care Stocks Moving In Tuesday's After-Market Session,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-08-01
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice,"NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (""Tiziana"" or the ""Company""), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on July 19, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the Company’s common shares on the Nasdaq Cap",2023-07-21
Tiziana Life Sciences gets Nasdaq notice for listing deficiency,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-07-21
Tiziana Life Sciences receives Nasdaq deficiency notice,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-07-21
Tesla directors settle lawsuit over compensation for $735 mln ,"Tesla Inc's directors agreed to settle a shareholder lawsuit challenging their compensation by returning to the company the value of 3.1 million stock options, worth $735 million, according to a Monday filing in a Delaware court. (Reporting by Tom Hals in Wilmington, Delaware...",2023-07-17
Publications And Positive Data From Multiple Trials: Six Months In Review For Tiziana Life Sciences (NASDAQ: TLSA),Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-07-10
TLSA: Reduced Microglial Activation in PET Scan,"By John Vandermosten, CFA NASDAQ:TLSA Tiziana Life Sciences PLC (NASDAQ:TLSA) reported new data from its ongoing non-active secondary progressive multiple sclerosis (na-SPMS) expanded access (EA) trial. Details of the new data were provided in a press release and in a webinar made available on June 5th. The call featured Dr. Howard Weiner, M.D., Principal Investigator for the EA trial, acting CEO",2023-06-20
We're Keeping An Eye On Tiziana Life Sciences' (NASDAQ:TLSA) Cash Burn Rate,"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...",2023-06-18
"Tiziana Life Sciences (NASDAQ: TLSA) Announces Positive Data In Its Secondary-Progressive Multiple Sclerosis Trial, What Could This Mean For The Company?",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-15
"Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer","NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer (COO). Dr. Davis, who also serves as the Chief Medical Officer (CMO), will now take on this additional role to further drive the company's growth and strategic initiatives an",2023-06-13
Tiziana Life Sciences appoints new operations chief,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-13
Tiziana Life Sciences appoints Matthew Davis as COO,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-13
Biotech Alert: Searches spiking for these stocks today,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-07
Tiziana's Foralumab Shown To Reduce Microglial Activation In MS Patients; Phase 2a Trial To Begin In Q3 2023,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-06
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis,"Figure 1 Baseline versus 3-month PET scans Results confirm positive signal previously reported in the first two Expanded Access patients who both subsequently demonstrated clinical improvementsPhase 2a trial in na-SPMS on track to begin in Q3 2023KOL webinar with Howard L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital being held today at 12:30 PM ET (details below) NEW YORK, June 05,",2023-06-05
Tiziana reports reduction in microglial activation with intranasal foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-05
"ATAI, NINE and TLSA are among pre market gainers",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-06-05
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS),"Webinar to take place on Monday, June 5, 2023 at 12:30 PM ETNEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to discuss the potential of foralumab in non-active secondary progressive multiple sclerosis (na SPMS) on Monday, June 5, 2023 at 12:30 PM ET. The event will feature",2023-05-25
Tiziana Life Sciences to host KOL webinar on foralumab,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-05-25
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform,"NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new Webull Corporate Communication services platform. The Tiziana portal on the Webull platform will help provide the Company with a direct line of communication with its shareholders while providing Tiziana's followers",2023-05-23
Tiziana Life Sciences participates in Webull Corporate Communication platform,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-05-23
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17,"NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at the Hanson Wade Novel Nasal Formulation and Delivery Summit on May 17 in San Diego. “I was truly honored when Hanson Wade contacted me requesting that I speak at its Novel Nasal Formulation and Delivery Summit1,",2023-05-17
"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Editas Medicine (EDIT) and Tiziana Life Sciences (TLSA)",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-05-05
"Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Tiziana Life Sciences (TLSA)",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-05-05
TLSA: SPMS Phase II to Proceed,"By John Vandermosten, CFA NASDAQ:TLSA Tiziana Life Sciences PLC (NASDAQ:TLSA) is preparing to launch a Phase II clinical trial in non-active secondary progressive multiple sclerosis (SPMS) in 3Q:23. Support for the trial comes from the early but promising data that has been generated in the expanded access program. In this note we will review Tiziana’s efforts to advance intranasal foralumab in",2023-05-02
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference,"There are no effective treatments for intracerebral hemorrhage (ICH), which has a 30% to 40% mortality rateIntranasal anti-CD3 mAb treatment showed a reduction in Intracerebral Hemorrhage injury severityIntranasal foralumab could represent a novel therapeutic approach for treating ICH and potentially other types of acute brain injury NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough",2023-04-27
Tiziana Life Sciences announces findings from nasal anti-CD3 mAb treatment,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-27
"Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update","NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months ended December 31, 2022, and provided a corporate update on its lead programs in development. Gabriele Cerrone, Executive Chairman, founder and interim Chief Executive Officer of Tiziana, commented, “After announcing",2023-04-26
Tiziana Life Sciences reports FY results,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-26
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule,"NEW YORK, April 24, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq",2023-04-24
Tiziana Life Sciences regains compliance with Nasdaq listing minimum bid price rule,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-24
Tiziana Life regains compliance with Nasdaq listing minimum bid price rule,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-24
Tiziana Life Sciences plans to file Investigational New Drug Application for Alzheimer's treatment,Tiziana Life Sciences chief medical officer Dr Matthew Davis joins Proactive's Natalie Stoberman to share how the company is planning to file an Investigational New Drug (IND) application for intra...,2023-04-21
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023,"Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab Alzheimer’s IND filingAlzheimer’s patients will be administered 3-months of intranasal foralumab to study effects on neuroinflammation caused microglia activation NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company",2023-04-20
Tiziana Life Sciences to file alzheimer`s IND for intranasal foralumab in Q2,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-20
"Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis","Tiziana Life Sciences (NASDAQ:TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the clinical stage.",2023-04-19
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes,"CD3 antibody has emerged as an established and attractive target for Type 1 diabetes after the $2.9 billion acquisition of Provention Bio by SanofiMechanism of Action of Tiziana’s first-in-class, only fully human CD3 antibody, intranasal foralumab, makes it an ideal candidate for Type 1 diabetes Tiziana initiates program to study both the treatment and the delay of type 1 diabetes using its convenient self-administered intranasal foralumab NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Tiziana Lif",2023-04-18
Tiziana Life Sciences initiates program to develop foralumab in T1D,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-18
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences’ (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise,"Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies are treatments that seek to reduce inflammation in the body, but all these immunosuppressive drugs use either animal or humanized antibodies, which are less effective than fully human antibodies.",2023-04-17
Tiziana Life Sciences pursuing development of intranasal foralumab for Long COVID treatment,Tiziana Life Sciences chief medical officer Dr Matthew Davis joins Proactive's Natalie Stoberman to explain how the company is pursuing the development of intranasal foralumab for the treatment of ...,2023-04-17
Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce ��� Tiziana Life Sciences` (NASDAQ:TLSA) First-in-Class Foralumab Is Showing Promise,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-17
EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients,"Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia cells, a key component in this disease's pathogenesis. ""We anticipate entering into a Phase 2a placebo-controlled clinical trial upon successful feedback from the FDA"", commented Matthew Davis, Chief Medical Officer of Tiziana. ""The use of PET Scans will allow us to determine if intranasal foralumab",2023-04-13
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID,"Long COVID remains a high unmet need causing a myriad of complications for patients and costing the U.S. healthcare system an estimated $2.6 trillionThe role of activated microglia is well-established in the pathogenesis of Long COVID and Tiziana’s first-in-class intranasal foralumab dampens activated microglia NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation thera",2023-04-13
Tiziana stock pops on plans to develop intranasal foralumab for Long COVID,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-13
Tiziana to develop intranasal foralumab for the treatment of long COVID,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,2023-04-13
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai,"Exhibition will run from March 31st to May 21st, 2023, at Prada Rong ZhaiScientific Conference will be held on April 20th, 2023, at Prada Rong Zhai NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that poster presentations on intranasal foralumab are being presented at the “Preserving the Brain” scientifi",2023-04-10
